Acinterferon alfa

阿克干扰素 α

Report date: 2025/11/10 15:46:55

Base Information

Drug NameAcinterferon alfa
Drug Alias Name重组高效抗肿瘤抗病毒蛋白（杰华生物）Recombinant cytokine gene derived protein injectionRecombinant anti-tumour and anti-virus protein重组细胞因子基因衍生蛋白注射液Recombinant cytokine gene derived protein (Genova Biotech) +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Pancreatic NeoplasmsColorectal Neoplasms +[6] 
Global Approved IndicationsHepatitis B
Approved Indications in ChinaHepatitis B
Original Approved Country/TerritoryMainland China
Original Approved Date2018/04/12
Country/TerritoryCanadaUkraineTurkey +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenova Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGenova IncBeijing Genova Biotech Company Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsColorectal NeoplasmsMelanoma +[5] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeS01AD05
Related LinksN/A